Reviews Fentora


No reviews yet.

Fentora Drug Description
FENTORA®
(fentanyl buccal) Tablet
Each tablet contains fentanyl citrate equivalent to fentanyl base: 100,
200, 300, 400, 600 and 800 mcg
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.

Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper patient
selection (e.g., use in opioid non-tolerant patients) and/or improper dosing.
The substitution of FENTORA for any other fentanyl product may result in fatal
overdose.
FENTORA is indicated only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8
mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily
for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression could
occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid
non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from Actiq®
to FENTORA . Carefully consult the Initial Dosing Recommendations table.
(See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic profile
of FENTORA compared to other fentanyl products that result in clinically
important differences in the extent of absorption of fentanyl. As a result of
these differences, the substitution of FENTORA for any other fentanyl
product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one additional
dose using the same strength and must wait at least 4 hours before taking another
dose. (See DOSAGE AND ADMINISTRATION)
FENTORA contains fentanyl, an opioid agonist and a Schedule
II controlled substance, with an abuse liability similar to other opioid analgesics.
FENTORA can be abused in a manner similar to other opioid agonists, legal
or illicit. This should be considered when prescribing or dispensing FENTORA
in situations where the physician or pharmacist is concerned about an increased
risk of misuse, abuse or diversion. Schedule II opioid substances which include
morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest
potential for abuse and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that FENTORA contains
a medicine in an amount which can be fatal to a child. Patients and their
caregivers must be instructed to keep all tablets out of the reach of children.
(See Information for Patients and Caregivers for
disposal instructions.)
FENTORA is intended to be used only in the care of opioid tolerant
cancer patients and only by healthcare professionals who are knowledgeable of
and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

DRUG DESCRIPTION



What are the possible side effects of fentanyl buccal (Fentora)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl buccal and call your doctor at once if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, drowsiness, or confusion;
cold, clammy skin; or
feeling light-headed or fainting.

Less serious side effects may include:

...
Read All Potential Side Effects for Fentora »




FENTORA (fentanyl buccal tablet) is a potent opioid analgesic, intended for buccal mucosal administration. FENTORA is formulated as a flat-faced, round, beveled-edge white tablet.
FENTORA is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.
FENTORA employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.
Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate,
sodium carbonate, citric acid, and magnesium stearate.Last reviewed on RxList: 12/29/2009




Fentora Drug Description
FENTORA®
(fentanyl buccal) Tablet
Each tablet contains fentanyl citrate equivalent to fentanyl base: 100,
200, 300, 400, 600 and 800 mcg
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.

Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper patient
selection (e.g., use in opioid non-tolerant patients) and/or improper dosing.
The substitution of FENTORA for any other fentanyl product may result in fatal
overdose.
FENTORA is indicated only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8
mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily
for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression could
occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid
non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from Actiq®
to FENTORA . Carefully consult the Initial Dosing Recommendations table.
(See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic profile
of FENTORA compared to other fentanyl products that result in clinically
important differences in the extent of absorption of fentanyl. As a result of
these differences, the substitution of FENTORA for any other fentanyl
product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one additional
dose using the same strength and must wait at least 4 hours before taking another
dose. (See DOSAGE AND ADMINISTRATION)
FENTORA contains fentanyl, an opioid agonist and a Schedule
II controlled substance, with an abuse liability similar to other opioid analgesics.
FENTORA can be abused in a manner similar to other opioid agonists, legal
or illicit. This should be considered when prescribing or dispensing FENTORA
in situations where the physician or pharmacist is concerned about an increased
risk of misuse, abuse or diversion. Schedule II opioid substances which include
morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest
potential for abuse and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that FENTORA contains
a medicine in an amount which can be fatal to a child. Patients and their
caregivers must be instructed to keep all tablets out of the reach of children.
(See Information for Patients and Caregivers for
disposal instructions.)
FENTORA is intended to be used only in the care of opioid tolerant
cancer patients and only by healthcare professionals who are knowledgeable of
and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

DRUG DESCRIPTION



What are the possible side effects of fentanyl buccal (Fentora)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl buccal and call your doctor at once if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, drowsiness, or confusion;
cold, clammy skin; or
feeling light-headed or fainting.

Less serious side effects may include:

...
Read All Potential Side Effects for Fentora »




FENTORA (fentanyl buccal tablet) is a potent opioid analgesic, intended for buccal mucosal administration. FENTORA is formulated as a flat-faced, round, beveled-edge white tablet.
FENTORA is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.
FENTORA employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.
Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate,
sodium carbonate, citric acid, and magnesium stearate.Last reviewed on RxList: 12/29/2009




Fentora Drug Description
FENTORA®
(fentanyl buccal) Tablet
Each tablet contains fentanyl citrate equivalent to fentanyl base: 100,
200, 300, 400, 600 and 800 mcg
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.

Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper patient
selection (e.g., use in opioid non-tolerant patients) and/or improper dosing.
The substitution of FENTORA for any other fentanyl product may result in fatal
overdose.
FENTORA is indicated only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8
mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily
for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression could
occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid
non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from Actiq®
to FENTORA . Carefully consult the Initial Dosing Recommendations table.
(See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic profile
of FENTORA compared to other fentanyl products that result in clinically
important differences in the extent of absorption of fentanyl. As a result of
these differences, the substitution of FENTORA for any other fentanyl
product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one additional
dose using the same strength and must wait at least 4 hours before taking another
dose. (See DOSAGE AND ADMINISTRATION)
FENTORA contains fentanyl, an opioid agonist and a Schedule
II controlled substance, with an abuse liability similar to other opioid analgesics.
FENTORA can be abused in a manner similar to other opioid agonists, legal
or illicit. This should be considered when prescribing or dispensing FENTORA
in situations where the physician or pharmacist is concerned about an increased
risk of misuse, abuse or diversion. Schedule II opioid substances which include
morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest
potential for abuse and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that FENTORA contains
a medicine in an amount which can be fatal to a child. Patients and their
caregivers must be instructed to keep all tablets out of the reach of children.
(See Information for Patients and Caregivers for
disposal instructions.)
FENTORA is intended to be used only in the care of opioid tolerant
cancer patients and only by healthcare professionals who are knowledgeable of
and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

DRUG DESCRIPTION



What are the possible side effects of fentanyl buccal (Fentora)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl buccal and call your doctor at once if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, drowsiness, or confusion;
cold, clammy skin; or
feeling light-headed or fainting.

Less serious side effects may include:

...
Read All Potential Side Effects for Fentora »




FENTORA (fentanyl buccal tablet) is a potent opioid analgesic, intended for buccal mucosal administration. FENTORA is formulated as a flat-faced, round, beveled-edge white tablet.
FENTORA is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.
FENTORA employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.
Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate,
sodium carbonate, citric acid, and magnesium stearate.Last reviewed on RxList: 12/29/2009




Fentora Drug Description
FENTORA®
(fentanyl buccal) Tablet
Each tablet contains fentanyl citrate equivalent to fentanyl base: 100,
200, 300, 400, 600 and 800 mcg
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.

Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper patient
selection (e.g., use in opioid non-tolerant patients) and/or improper dosing.
The substitution of FENTORA for any other fentanyl product may result in fatal
overdose.
FENTORA is indicated only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8
mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily
for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression could
occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid
non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from Actiq®
to FENTORA . Carefully consult the Initial Dosing Recommendations table.
(See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic profile
of FENTORA compared to other fentanyl products that result in clinically
important differences in the extent of absorption of fentanyl. As a result of
these differences, the substitution of FENTORA for any other fentanyl
product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one additional
dose using the same strength and must wait at least 4 hours before taking another
dose. (See DOSAGE AND ADMINISTRATION)
FENTORA contains fentanyl, an opioid agonist and a Schedule
II controlled substance, with an abuse liability similar to other opioid analgesics.
FENTORA can be abused in a manner similar to other opioid agonists, legal
or illicit. This should be considered when prescribing or dispensing FENTORA
in situations where the physician or pharmacist is concerned about an increased
risk of misuse, abuse or diversion. Schedule II opioid substances which include
morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest
potential for abuse and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that FENTORA contains
a medicine in an amount which can be fatal to a child. Patients and their
caregivers must be instructed to keep all tablets out of the reach of children.
(See Information for Patients and Caregivers for
disposal instructions.)
FENTORA is intended to be used only in the care of opioid tolerant
cancer patients and only by healthcare professionals who are knowledgeable of
and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

DRUG DESCRIPTION



What are the possible side effects of fentanyl buccal (Fentora)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl buccal and call your doctor at once if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, drowsiness, or confusion;
cold, clammy skin; or
feeling light-headed or fainting.

Less serious side effects may include:

...
Read All Potential Side Effects for Fentora »




FENTORA (fentanyl buccal tablet) is a potent opioid analgesic, intended for buccal mucosal administration. FENTORA is formulated as a flat-faced, round, beveled-edge white tablet.
FENTORA is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.
FENTORA employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.
Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate,
sodium carbonate, citric acid, and magnesium stearate.Last reviewed on RxList: 12/29/2009




Fentora Drug Description
FENTORA®
(fentanyl buccal) Tablet
Each tablet contains fentanyl citrate equivalent to fentanyl base: 100,
200, 300, 400, 600 and 800 mcg
PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE IMPORTANT WARNINGS IN THIS LABEL.

Reports of serious adverse events, including deaths in patients treated
with FENTORA have been reported. Deaths occurred as a result of improper patient
selection (e.g., use in opioid non-tolerant patients) and/or improper dosing.
The substitution of FENTORA for any other fentanyl product may result in fatal
overdose.
FENTORA is indicated only for the management of breakthrough
pain in patients with cancer who are already receiving and who are tolerant
to around-the-clock opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking around-the-clock
medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg
of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8
mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily
for a week or longer.
FENTORA is not indicated for use in opioid non-tolerant patients
including those with only as needed (PRN) prior exposure.
FENTORA is contraindicated in the management of acute or postoperative
pain including headache/migraine. Life-threatening respiratory depression could
occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid
non-tolerant patients.
When prescribing, do not convert patients on a mcg per mcg basis from Actiq®
to FENTORA . Carefully consult the Initial Dosing Recommendations table.
(See DOSAGE AND ADMINISTRATION, Table 7.)
When dispensing, do not substitute a FENTORA prescription for other
fentanyl products. Substantial differences exist in the pharmacokinetic profile
of FENTORA compared to other fentanyl products that result in clinically
important differences in the extent of absorption of fentanyl. As a result of
these differences, the substitution of FENTORA for any other fentanyl
product may result in fatal overdose.
Special care must be used when dosing FENTORA. If the breakthrough pain
episode is not relieved after 30 minutes, patients may take ONLY one additional
dose using the same strength and must wait at least 4 hours before taking another
dose. (See DOSAGE AND ADMINISTRATION)
FENTORA contains fentanyl, an opioid agonist and a Schedule
II controlled substance, with an abuse liability similar to other opioid analgesics.
FENTORA can be abused in a manner similar to other opioid agonists, legal
or illicit. This should be considered when prescribing or dispensing FENTORA
in situations where the physician or pharmacist is concerned about an increased
risk of misuse, abuse or diversion. Schedule II opioid substances which include
morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest
potential for abuse and risk of fatal overdose due to respiratory depression.
Patients and their caregivers must be instructed that FENTORA contains
a medicine in an amount which can be fatal to a child. Patients and their
caregivers must be instructed to keep all tablets out of the reach of children.
(See Information for Patients and Caregivers for
disposal instructions.)
FENTORA is intended to be used only in the care of opioid tolerant
cancer patients and only by healthcare professionals who are knowledgeable of
and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

DRUG DESCRIPTION



What are the possible side effects of fentanyl buccal (Fentora)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using fentanyl buccal and call your doctor at once if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, drowsiness, or confusion;
cold, clammy skin; or
feeling light-headed or fainting.

Less serious side effects may include:

...
Read All Potential Side Effects for Fentora »




FENTORA (fentanyl buccal tablet) is a potent opioid analgesic, intended for buccal mucosal administration. FENTORA is formulated as a flat-faced, round, beveled-edge white tablet.
FENTORA is designed to be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet and absorption of fentanyl across the oral mucosa.
FENTORA employs the OraVescent® drug delivery technology, which generates a reaction that releases carbon dioxide when the tablet comes in contact with saliva. It is believed that transient pH changes accompanying the reaction may optimize dissolution (at a lower pH) and membrane permeation (at a higher pH) of fentanyl through the buccal mucosa.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl)
propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water
partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic
solvents and sparingly soluble in water (1:40). The molecular weight of the
free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens
are 7.3 and 8.4. The compound has the following structural formula:








All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 microgram strength tablet contains 100 micrograms of fentanyl free base.
Inactive Ingredients: Mannitol, sodium starch glycolate, sodium bicarbonate,
sodium carbonate, citric acid, and magnesium stearate.Last reviewed on RxList: 12/29/2009





Other reviews about Fentora on wordpress

The Week's Corporate Gaffes On Wall Street (CEPH, MER, AGE, AMTD, BRLC)
  by 247wallst
This week's "Corporate Gaffe of the Week" should actually be shared by several companies.What may be the blue ribbon winner is Cephalon (NASDAQ:CEPH).  Reports noted that the company […]


Doctors Warned About Cephalon
  by DreamHealer
Sept 14, 2007┬á Drug manufacturer Cephalon Inc. recently sent out warning letters to doctors throughout the United States about the new risks found with Fentora. Fentora, a strong narcotic that […]


Important Safety Information for Fentora (Fentanyl buccal tablet)
  by heremias
On September 10th 2007, Cephalon, Inc., the manufacturer of Fentora (Fentanyl buccal tablet) issued both a Dear Doctor and a Dear Healthcare Professional letter in response to the […]


Cephalon's FDA Warning More of a Formality (CEPH)
  by 247wallst
Cephalon Inc. (NASDAQ:CEPH) is a biotech that has been under a bit of a low ceiling after its recent blunder regarding FENTORA.  As a reminder FENTORA is that […]


FDA Warns About Misuse Of Fentora Cancer Pain Drug
  by DreamHealer
The US Food and Drug Administration (FDA) has issued a warning, alerting health professionals and patients about the potential misuse and side effects of Fentora (fentanyl buccal), a […]


THE ACTIQ® AND FENTORA® ACCESS PROBLEM
  by painresearchadvocates
The Problem ACTIQ┬« and Fentora┬« are commercially formulated fentanyl products that dissolve under the tongue or in the inner side of the jaw ("buccal administration"). These products are simply […]


Fentora: FDA approved medication to manage breakthrough pain in cancer patients
  by naturalpainmanagement44
Cancer, in whatever form, is a complex disorder leading to debilitating pain in cancer patients. Because cancer leads to debilitating chronic and acute pain, many patients are on […]


Actiq® and Fentora® are two drugs used a
  by ltpepperlaw
Actiq┬« and Fentora┬« are two drugs used as painkillers. The active ingredient is fentanyl. Generally these drugs are prescribed to people who are considered opiod tolerant (those on […]


FDA Warning: Cancer causing painkiller Fentora Side Effect May, including death
  by naturalpainmanagement44
After two warnings (a warning, admonition 2) of the U.S. Federal Drug Administration is warning about adverse effects that Fentora (fentanyl buccal tablets) is in patients taking this […]


Deaths from improper use of Fentora Pain Med
  by painreliefsciatica88
Fentanyl buccal tablets marketed by Cephalon, Inc., as Fentora is a potent opioid analgesics are used to breakthrough pain in cancer patients who receive treat opioid treatment and […]



Other reviews about Fentora on web:

If you experience breakthrough pain, sudden flares of intense pain that ├â┬ó├é┬Ç├é┬ťbreak through├â┬ó├é┬Ç├é┬Ł your around-the-clock opioid medicine, FENTORA may be able to help. FENTORA | For breakthrough pain in opioid tolerant patients with ...


Accurate, FDA approved Fentora information for healthcare professionals and patients - brought to you by Drugs.com. Fentora Official FDA information, side effects and uses.


Fentora (fentanyl - buccal) is used to treat breakthrough cancer pain that is not controlled by other medicines. Includes Fentora side effects, interactions and indications. Fentora Information from Drugs.com


Fentanyl (also known as fentanil, brand names Sublimaze, Actiq, Durogesic, Duragesic, Fentora, Onsolis, Instanyl, and others) is a synthetic strong agonist at the mu and kappa ... Fentanyl - Wikipedia, the free encyclopedia


Learn about the prescription medication Fentora (Fentanyl Buccal Tablet), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Fentora (Fentanyl Buccal Tablet) Drug Information: Uses, Side ...


Learn about using FENTORA, including how to take FENTORA and finding the right dose to relieve your breakthrough pain. Using FENTORA | FENTORA.com


Fentora overdoses can cause the death of the person who overdoses on Fentora, our Fentora fentanyl Lawsuit Attorneys can review your overdose case today for free. Fentora Overdose Lawsuit Attorneys Fentanyl Death Dangers


If you or a loved one has experienced an overdose and/death relating to any of these products, call or email for a free consultation. Toll Free Steinberg Law Firm P.C. :: Nationwide Fentora® Litigation


Fentora, complete drug information. Including Fentora common uses, side effects and warnings. Fentora


What is Fentora (Fentanyl)? Fentanyl is a narcotic (opioid) pain medicine. Fentanyl buccal tablets are used to treat "breakthrough" cancer pain that is not controlled by other ... Fentora - Drugs & Treatments - Revolution Health





Featured Reviews

Reviews Halcinonide Cream

Halog Cream Drug Description HALOG® (halcinonide) Cream, USP 0.1% For Topical Use Only. Not For Ophthalmic Use. DRUG DESCRIPTION What are the possible side effects of halcinonide topical (Halog, Halog-E)? Get emergency...
Read More  |  Review This
Reviews Pseudoephedrine and Guaifenesin

Entex Pse Drug Description DRUG DESCRIPTION What are the possible side effects of guaifenesin and pseudoephedrine? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing;...
Read More  |  Review This
Reviews Decitabine Injection

Dacogen Drug Description DACOGEN® (decitabine) for Injection DRUG DESCRIPTION Dacogen (decitabine) for Injection contains decitabine (5-aza-2'deoxycitidine), an analogue of the natural nucleoside 2'-deoxycytidine. Decitabine is a...
Read More  |  Review This
Reviews Donepezil Hydrochloride

Aricept Drug Description ARICEPT® (donepezil hydrochloride) Tablet DRUG DESCRIPTION What are the possible side effects of donepezil (Aricept, Aricept ODT)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Coagulation Factor VIIa

Novoseven Drug Description NovoSeven® Coagulation Factor VIIa Recombinant DRUG DESCRIPTION What are the possible side effects of coagulation factor VIIa (NovoSeven, NovoSeven RT)? Get emergency medical help if you have any...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....